Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Last updated: November 6, 2025
Sponsor: Regeneron Pharmaceuticals
Overall Status: Planned

Phase

N/A

Condition

Leukemia

Multiple Myeloma

Cancer/tumors

Treatment

REGN5458

Clinical Study ID

NCT05164250
R5458-MM
  • All Genders

Study Summary

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Inclusion

Inclusion Criteria:

Exclusion

Exclusion Criteria:

Study Design

Treatment Group(s): 1
Primary Treatment: REGN5458
Phase:
Study Start date:
Estimated Completion Date:

Study Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.